IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.941
AS - Asia 4.013
EU - Europa 3.060
SA - Sud America 725
AF - Africa 303
Continente sconosciuto - Info sul continente non disponibili 251
OC - Oceania 8
Totale 21.301
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.670
SG - Singapore 1.617
RU - Federazione Russa 773
VN - Vietnam 696
CN - Cina 627
BR - Brasile 556
IT - Italia 549
HK - Hong Kong 518
IE - Irlanda 434
SE - Svezia 260
DE - Germania 244
FR - Francia 222
CI - Costa d'Avorio 192
GB - Regno Unito 192
IN - India 139
UA - Ucraina 122
CA - Canada 99
BD - Bangladesh 76
FI - Finlandia 65
JP - Giappone 51
AR - Argentina 50
MX - Messico 46
CO - Colombia 42
NL - Olanda 35
ZA - Sudafrica 34
PL - Polonia 32
IQ - Iraq 30
KR - Corea 30
TR - Turchia 27
ID - Indonesia 26
MA - Marocco 24
ES - Italia 23
PH - Filippine 23
CR - Costa Rica 21
EC - Ecuador 21
PK - Pakistan 21
BE - Belgio 19
VE - Venezuela 19
UZ - Uzbekistan 18
EE - Estonia 17
GT - Guatemala 16
TT - Trinidad e Tobago 16
CW - ???statistics.table.value.countryCode.CW??? 15
MY - Malesia 14
DK - Danimarca 13
NI - Nicaragua 13
SV - El Salvador 13
EG - Egitto 12
HN - Honduras 12
IL - Israele 12
CL - Cile 11
SA - Arabia Saudita 11
TN - Tunisia 11
PR - Porto Rico 10
TH - Thailandia 10
AU - Australia 8
BO - Bolivia 8
JO - Giordania 8
KZ - Kazakistan 8
BG - Bulgaria 7
PY - Paraguay 7
RO - Romania 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
CZ - Repubblica Ceca 6
GP - Guadalupe 6
DO - Repubblica Dominicana 5
DZ - Algeria 5
KG - Kirghizistan 5
LB - Libano 5
LT - Lituania 5
NP - Nepal 5
AZ - Azerbaigian 4
ET - Etiopia 4
JM - Giamaica 4
KE - Kenya 4
OM - Oman 4
PA - Panama 4
AL - Albania 3
AO - Angola 3
BH - Bahrain 3
CH - Svizzera 3
GA - Gabon 3
LU - Lussemburgo 3
LY - Libia 3
PE - Perù 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
GD - Grenada 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
KH - Cambogia 2
RS - Serbia 2
Totale 21.040
Salva come PNG Salva come JPEG
Città #
Ashburn 1.970
Des Moines 1.473
Singapore 1.197
Chandler 1.178
Fairfield 666
Dallas 577
San Jose 554
Hong Kong 505
Dublin 425
Council Bluffs 358
Wilmington 347
Boardman 325
Woodbridge 282
Houston 262
Seattle 256
New York 252
The Dalles 246
Ho Chi Minh City 224
Cambridge 216
Jacksonville 200
Abidjan 192
Princeton 178
Lawrence 167
Los Angeles 161
Beijing 160
Lauterbourg 158
Hanoi 150
San Mateo 142
Ann Arbor 135
Moscow 128
San Diego 103
Munich 81
Washington 74
Redmond 72
Santa Clara 70
Milan 66
Pune 65
Columbus 55
São Paulo 55
Chicago 50
London 49
Orem 47
Tokyo 44
Hefei 40
Helsinki 40
Rome 39
Da Nang 36
Haiphong 36
Buffalo 35
Ancona 34
Miano 34
Shanghai 32
Falls Church 31
Phoenix 30
Wuhan 29
Brooklyn 27
Clovis 27
Warsaw 27
Montreal 26
Frankfurt am Main 25
Atlanta 24
Guangzhou 24
Turku 24
Manchester 23
Denver 22
Stockholm 22
San Francisco 21
Turin 21
Brussels 19
Norwalk 19
San José 19
Chennai 18
Toronto 18
Amsterdam 17
Boston 17
Destin 17
Mexico City 17
Seoul 17
Dhaka 16
Milwaukee 16
Tashkent 16
Guatemala City 15
Jiaxing 15
Rio de Janeiro 15
Willemstad 15
Newark 14
Brasília 13
Can Tho 13
Bologna 12
Curitiba 12
Irving 12
Johannesburg 12
Managua 12
Poplar 12
San Salvador 12
Baghdad 11
Jakarta 11
Medellín 11
Porto Alegre 11
Bogotá 10
Totale 15.108
Salva come PNG Salva come JPEG
Nome #
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 236
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 223
Immunotherapy in genitourinary cancers: Where are we going? 216
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 212
Are liver nested stromal epithelial tumors always low aggressive? 211
Designing novel immunocombinations in metastatic renal cell carcinoma 208
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 207
Predicting future cancer burden in the United States by artificial neural networks 205
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 192
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 186
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 181
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 180
Exploring the Spectrum of Kidney Ciliopathies 177
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 169
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 169
An update on investigational therapies that target STAT3 for the treatment of cancer 168
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 166
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 166
Microbiome and cancers, with focus on genitourinary tumors 164
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 163
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 163
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 162
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 158
Molecular characterization of testicular germ cell tumors using tissue microdissection 156
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 154
Bone targeting agents in patients with metastatic prostate cancer: State of the art 154
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 154
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 153
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 151
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 149
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 148
Is There a Role for Immunotherapy in Prostate Cancer? 148
Molecular diagnostics in uro-oncology 146
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 146
Pd-l1 inhibitors for the treatment of prostate cancer 145
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 144
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 144
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 142
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 141
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 140
Epigenetic modifications and modulators in prostate cancer 140
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer 139
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 139
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 139
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 138
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 138
The identification of immunological biomarkers in kidney cancers 138
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 137
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 136
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 136
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 136
From undergraduate medical school student to visible pathologist 136
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 136
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 135
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 134
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 134
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 134
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 134
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 132
The human microbiota and prostate cancer: Friend or foe? 131
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 131
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 130
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 130
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 130
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 130
An update on immunotherapy in uro-oncology 130
Biphasic Tumors of the Urogenital Tract: Selected Topics 130
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 129
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 129
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers 128
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 128
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 127
Immune checkpoint inhibitors for the treatment of bladder cancer 127
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 127
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 125
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 125
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 125
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 124
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 124
Variants of Bladder Cancer: The Pathologist's Point of View 124
Exploring small extracellular vesicles for precision medicine in prostate cancer 123
Renal Cell Carcinoma: genomic landscape and clinical implications 123
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 122
Molecular Pathology of Urothelial Carcinoma 121
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 121
Epigenetic modulations and lineage plasticity in advanced prostate cancer 120
Pathology without microscope: From a projection screen to a virtual slide 120
Variants and new entities of bladder cancer 119
Treating prostate cancer by antibody-drug conjugates 118
INTRADUCTAL CARCINOMA IN LOW- AND INTERMEDIATE-RISK PROSTATE CANCER: PATHOLOGICAL AND CLINICAL RELEVANCE 118
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 117
Agent-Based Learning Model for the Obesity Paradox in RCC 117
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 117
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 116
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 116
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 116
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 115
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 115
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples 115
Totale 14.474
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.920
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022995 0 0 0 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.610 282 45 138 162 248 358 22 49 5 57 24 220
2024/20252.948 376 229 35 52 103 121 226 107 750 305 259 385
2025/20267.265 396 441 441 288 1.024 469 1.490 741 733 669 178 395
2026/20271.456 192 226 289 749 0 0 0 0 0 0 0 0
Totale 21.301